Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Current Deferred Revenue data on file, last reported at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 88.59% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (down 88.59% YoY), and the FY2025 full-year result was $4.8 million, down 91.27% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $3.2 million, down from $4.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $235.5 million in Q4 2022 and bottomed at $2.5 million in Q3 2025.
• The 5-year median for Current Deferred Revenue is $69.0 million (2024), against an average of $65.8 million.
• The widest annual swing landed in 2024, when Current Deferred Revenue jumped 114.7%; it then sank 96.42% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $235.5 million in 2022, then plunged by 56.37% to $102.8 million in 2023, then plunged by 46.01% to $55.5 million in 2024, then slumped by 91.27% to $4.8 million in 2025, then tumbled by 33.68% to $3.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $3.2 million (Q1 2026), $4.8 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.

Peer Comparison